Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 726

1.

IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, Lehmann HC.

J Neuroimmunol. 2014 Jun 19. pii: S0165-5728(14)00178-7. doi: 10.1016/j.jneuroim.2014.06.007. [Epub ahead of print]

PMID:
25002077
[PubMed - as supplied by publisher]
2.

Bacteria and their cell wall components uniformly co-activate IL-17-producing, thymocytes.

Weber A, Zimmermann C, Kieseier BC, Hartung HP, Hofstetter HH.

Clin Exp Immunol. 2014 Jul 4. doi: 10.1111/cei.12414. [Epub ahead of print]

PMID:
24995465
[PubMed - as supplied by publisher]
3.

CD19 as a molecular target in CNS autoimmunity.

Stüve O, Warnke C, Deason K, Stangel M, Kieseier BC, Hartung HP, von Büdingen HC, Centonze D, Forsthuber TG, Knappertz V.

Acta Neuropathol. 2014 Aug;128(2):177-90. doi: 10.1007/s00401-014-1313-z. Epub 2014 Jul 4.

PMID:
24993505
[PubMed - in process]
4.

Alemtuzumab: The advantages and challenges of a novel therapy in MS.

Menge T, Stüve O, Kieseier BC, Hartung HP.

Neurology. 2014 Jul 1;83(1):87-97. Epub 2014 Jun 11. Review.

PMID:
24920854
[PubMed - as supplied by publisher]
5.

Interferon beta-1a for multiple sclerosis: old drug, new clothes.

Hartung HP.

Lancet Neurol. 2014 Jul;13(7):638-9. doi: 10.1016/S1474-4422(14)70100-0. Epub 2014 May 28. No abstract available.

PMID:
24878062
[PubMed - in process]
6.

Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany.

Prestel J, Volkers P, Mentzer D, Lehmann HC, Hartung HP, Keller-Stanislawski B; for the GBS Study Group.

Pharmacoepidemiol Drug Saf. 2014 May 10. doi: 10.1002/pds.3638. [Epub ahead of print]

PMID:
24817531
[PubMed - as supplied by publisher]
7.

The new therapeutic landscape in multiple sclerosis: exciting times and new perspectives.

Hartung HP, Kieseier BC.

Curr Opin Neurol. 2014 Jun;27(3):243-5. doi: 10.1097/WCO.0000000000000101. No abstract available.

PMID:
24751962
[PubMed - in process]
8.

Cerebrospinal Fluid JC Virus Antibody Index for Diagnosis of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.

Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kümpfel T, Mäurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, Hermsen D, Kleinschnitz C, Hartung HP, Wattjes MP, Svenningson A, Major E, Olsson T, Kieseier BC, Adams O.

Ann Neurol. 2014 Apr 11. doi: 10.1002/ana.24153. [Epub ahead of print]

PMID:
24729444
[PubMed - as supplied by publisher]
9.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P.

Neurology. 2014 Apr 29;82(17):1491-8. doi: 10.1212/WNL.0000000000000355. Epub 2014 Mar 28.

PMID:
24682966
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Interleukin-17 impedes Schwann cell-mediated myelination.

Stettner M, Lohmann B, Wolffram K, Weinberger JP, Dehmel T, Hartung HP, Mausberg AK, Kieseier BC.

J Neuroinflammation. 2014 Mar 29;11:63. doi: 10.1186/1742-2094-11-63.

PMID:
24678820
[PubMed - in process]
Free PMC Article
11.

Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis.

Lill CM, Schilling M, Ansaloni S, Schröder J, Jaedicke M, Luessi F, Schjeide BM, Mashychev A, Graetz C, Akkad DA, Gerdes LA, Kroner A, Blaschke P, Hoffjan S, Winkelmann A, Dörner T, Rieckmann P, Steinhagen-Thiessen E, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Buttmann M, Kümpfel T, Kubisch C, Zettl UK, Epplen JT, Zipp F, Bertram L.

Neurogenetics. 2014 May;15(2):129-34. doi: 10.1007/s10048-014-0396-y. Epub 2014 Mar 18.

PMID:
24638856
[PubMed - in process]
12.

Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics.

Derksen A, Ritter C, Athar P, Kieseier BC, Mancias P, Hartung HP, Sheikh KA, Lehmann HC.

Muscle Nerve. 2014 Feb 25. doi: 10.1002/mus.24226. [Epub ahead of print]

PMID:
24616124
[PubMed - as supplied by publisher]
13.

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J; ATAMS Study Group.

Lancet Neurol. 2014 Apr;13(4):353-63. doi: 10.1016/S1474-4422(14)70028-6. Epub 2014 Mar 6.

PMID:
24613349
[PubMed - indexed for MEDLINE]
14.

Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease.

Matusch A, Saft C, Elmenhorst D, Kraus PH, Gold R, Hartung HP, Bauer A.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1210-20. doi: 10.1007/s00259-014-2724-8. Epub 2014 Feb 25.

PMID:
24566949
[PubMed - in process]
15.

Immune regulation of multiple sclerosis.

Hartung HP, Aktas O, Menge T, Kieseier BC.

Handb Clin Neurol. 2014;122:3-14. doi: 10.1016/B978-0-444-52001-2.00001-7.

PMID:
24507511
[PubMed - in process]
16.

Monomethylfumarate reduces in vitro migration of mononuclear cells.

Dehmel T, Döbert M, Pankratz S, Leussink VI, Hartung HP, Wiendl H, Kieseier BC.

Neurol Sci. 2014 Jul;35(7):1121-5. doi: 10.1007/s10072-014-1663-2. Epub 2014 Feb 7.

PMID:
24504620
[PubMed - in process]
17.

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.

Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M; oral cladribine for early MS (ORACLE MS) Study Group.

Lancet Neurol. 2014 Mar;13(3):257-67. doi: 10.1016/S1474-4422(14)70005-5. Epub 2014 Feb 4.

PMID:
24502830
[PubMed - indexed for MEDLINE]
18.

Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study.

Doerner M, Beckmann K, Knappertz V, Kappos L, Hartung HP, Filippi M, O'Connor PW, Arnason B, Cook S, Jeffery D, Comi G, Limmroth V.

Eur Neurol. 2014;71(3-4):173-9. doi: 10.1159/000355530. Epub 2014 Jan 21.

PMID:
24457374
[PubMed - in process]
19.

Vitamin D as an early predictor of multiple sclerosis activity and progression.

Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C.

JAMA Neurol. 2014 Mar;71(3):306-14. doi: 10.1001/jamaneurol.2013.5993.

PMID:
24445558
[PubMed - indexed for MEDLINE]
20.

Novel therapeutic options for multiple sclerosis.

Curtin F, Hartung HP.

Expert Rev Clin Pharmacol. 2014 Jan;7(1):91-104. doi: 10.1586/17512433.2014.865517. Epub 2013 Dec 10.

PMID:
24325127
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk